HCV NS5A inhibitors disrupt replication factory formation: A novel mechanism of antiviral action

Gastroenterology

Volumn 147, Issue 5, 2014, Pages 959-962

  Eyre, Nicholas S ^a   Beard, Michael R ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; LEDIPASVIR; OMBITASVIR; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BIOGENESIS; DIMERIZATION; ENDOPLASMIC RETICULUM; HEPATITIS C VIRUS; MEMBRANE VESICLE; MOLECULAR DOCKING; NONHUMAN; OLIGOMERIZATION; REPLICON; REVIEW; RNA REPLICATION; VIRUS ASSEMBLY; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CELL MEMBRANE; DRUG EFFECTS; HEPACIVIRUS; HUMAN; LIVER CELL;

ANTIVIRAL AGENTS; CELL MEMBRANE; HEPACIVIRUS; HEPATOCYTES; HUMANS; IMIDAZOLES; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84908266815     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.09.024     Document Type: Editorial

References (24)

1. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
2. F. Poordad, J. McCone Jr., and B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
3. X. Forns, E. Lawitz, and S. Zeuzem Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial Gastroenterology 146 2014 1669 1679.e3
4. E. Lawitz, A. Mangia, and D. Wyles Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
5. C. Berger, I. Romero-Brey, and D. Radujkovic Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication Gastroenterology 147 2014 1094 1105
6. M. Gao, R.E. Nettles, and M. Belema Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
7. O. Belda, and P. Targett-Adams Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein Virus Res 170 2012 1 14
8. M. Gao Antiviral activity and resistance of HCV NS5A replication complex inhibitors Curr Opin Virol 3 2013 514 520
9. J.M. Pawlotsky NS5A inhibitors in the treatment of hepatitis C J Hepatol 59 2013 375 382
10. R.A. Love, O. Brodsky, and M.J. Hickey Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus J Virol 83 2009 4395 4403
11. T.L. Tellinghuisen, J. Marcotrigiano, and C.M. Rice Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase Nature 435 2005 374-39
12. P. Targett-Adams, E.J. Graham, and J. Middleton Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action J Virol 85 2011 6353 6368
13. C. Lee, H. Ma, and J.Q. Hang The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein Virology 414 2011 10 18
14. D. Qiu, J.A. Lemm, and D.R. O'Boyle 2nd The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization J Gen Virol 92 2011 2502 2511
15. R.A. Fridell, D. Qiu, and L. Valera Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 J Virol 85 2011 7312 7320
16. J.A. Lemm, D. O'Boyle 2nd, and M. Liu Identification of hepatitis C virus NS5A inhibitors J Virol 84 2010 482 491
17. D.R. McGivern, T. Masaki, and S. Williford Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors Gastroenterology 147 2014 453 462.e7
18. S. Reiss, C. Harak, and I. Romero-Brey The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A PLoS Pathog 9 2013 e1003359
19. D. Ross-Thriepland, and M. Harris Insights into the Complexity and Functionality of Hepatitis C Virus NS5A Phosphorylation J Virol 88 2014 1421 1432
20. P. Ferraris, E. Beaumont, and R. Uzbekov Sequential biogenesis of host cell membrane rearrangements induced by hepatitis C virus infection Cell Mol Life Sci 70 2013 1297 1306
21. D. Paul, S. Hoppe, and G. Saher Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment J Virol 87 2013 10612 10627
22. I. Romero-Brey, A. Merz, and A. Chiramel Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication PLoS Pathog 8 2012 e1003056
23. S. Reiss, I. Rebhan, and P. Backes Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment Cell Host Microbe 9 2011 32 45
24. H. Wang, J.W. Perry, and A.S. Lauring Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking Gastroenterology 146 2014 1373 1385 e1-11